Institute Report
Quantifying Differences in Female and Male Healthcare
Evidence from Epidemiology, Trials, Therapeutics, Medicine Use, and Investments
Nov 18, 2025

IQVIA customers will be able to access these reports at no cost via discount codes. If you are an existing customer, please contact your account representative or send a request for the code to Info@IQVIAInstitute.org.

These reports are view-only via browser or app, and may be viewed on up to ten personal devices.

This report is licensed for individual use only. It may not be shared, reproduced, distributed, or transferred in any form to any other person or entity without prior written consent. This report is subject to the terms and conditions of the IQVIA Licensing and Services Agreement General Terms and Conditions (April 2022) available at ( https://ogc.iqvia.com/Contracts/LSA-0422). By purchasing this report, you agree that your use of the report is bound by these General Terms.

Assessing sex and gender parity in life sciences is critically important as findings can help to influence the fairness, effectiveness, and inclusivity of the medicines being developed, participation in clinical trials, and the use of medicines available commercially. Women tend to live longer than men but often experience more chronic conditions and disability, while men face higher rates of early mortality from acute causes.

The purpose of this report is to highlight different frameworks for assessing and benchmarking which diseases are studied in clinical trials, and whether trial participation, numbers of new drug launches, and use of medicines reflect sex and/or gender epidemiology and burden of disease.

Institute Report FAQs

Answers to most questions regarding IQVIA Institute reports for purchase may be found on our FAQ page.
Learn more
Contact Us